Friday, July 10, 2026

Drug profile · INN

calaspargase pegol-mknl

calaspargase pegol-mknl (ASPARLAS) is a asparagine hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — calaspargase pegol-mknl
US status
approved
Class
Route
INTRAVENOUS
Patents
0
Programs
0
Data quality
0.84

Quick answer

calaspargase pegol-mknl (ASPARLAS) is a asparagine hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.

Key facts

INN calaspargase pegol-mknl
Brand ASPARLAS
Mechanism Asparagine hydrolytic enzyme
Target Asparagine
Route INTRAVENOUS
Formulation INJECTABLE

Mechanism of action

Asparagine hydrolytic enzyme

Primary target: Asparagine

Approval history

Authority Status Date
FDA approved

Related & competitor drugs

  1. asparaginase erwinia chrysanthemi (recombinant)-rywn Asparagine hydrolytic enzyme
  2. crisantaspase Antineoplastic and immunomodulating agents (L01)
  3. asparaginase Antineoplastic and immunomodulating agents (L01)
  4. pegaspargase Antineoplastic and immunomodulating agents (L01)

Frequently asked questions

What is calaspargase pegol-mknl?

calaspargase pegol-mknl (ASPARLAS) is a asparagine hydrolytic enzyme. Route of administration: intravenous. Current US regulatory status: approved.

What is the brand name for calaspargase pegol-mknl?

ASPARLAS is a marketed brand name for calaspargase pegol-mknl. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of calaspargase pegol-mknl?

calaspargase pegol-mknl has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.